From: Allergen Immunotherapy (AIT): a prototype of Precision Medicine
• Assessment of prevalence and severity of allergic diseases. |  |
• Phenotypic characterisation of allergic patients, stratification of patients, characterisation of severe chronic upper airway disease (SCUAD) patients and characterisation of patients to be treated by AIT. |  |
• Randomised controlled trials (placebo-controlled or real life cluster randomised trials): assessment of efficacy (during the allergen exposure) and safety (during AIT administration). |  |
• Follow up of patients in clinical settings during AIT. |  |
• Follow up of patients in clinical settings after AIT has been stopped. |  |